Compare RYTM & M Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | M |
|---|---|---|
| Founded | 2008 | 1830 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.5B |
| IPO Year | 2017 | 2003 |
| Metric | RYTM | M |
|---|---|---|
| Price | $115.63 | $25.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 13 |
| Target Price | ★ $131.14 | $20.09 |
| AVG Volume (30 Days) | 640.7K | ★ 4.6M |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 28.34 | 12.08 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $22,621,000,000.00 |
| Revenue This Year | $55.34 | N/A |
| Revenue Next Year | $86.06 | N/A |
| P/E Ratio | ★ N/A | $109.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.50 | $12.02 |
| 52 Week High | $122.20 | $26.59 |
| Indicator | RYTM | M |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 56.27 |
| Support Level | $98.76 | $22.32 |
| Resistance Level | $113.03 | $25.87 |
| Average True Range (ATR) | 4.84 | 0.85 |
| MACD | 0.15 | 0.11 |
| Stochastic Oscillator | 98.64 | 61.03 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.